https://taurx.com/assessment-of-clinical-and-neuroimaging-efficacy-of-treatment-targeting-tau-pathology-in-mild-cognitive-impairment-and-mild-to-moderate-alzheimers-disease-with-hydromethylthionine-mesylate-using-external-control-data2026-04-29T07:19:46-07:00weekly0.5https://taurx.com/clinical-imaging-and-blood-biomarker-outcomes-in-a-phase-3-clinical-trial-of-tau-aggregation-inhibitor-hydromethylthionine-mesylate-in-mild-cognitive-impairment-and-mild-to-moderate-dementia-due-to-alzheimers-disease2026-04-29T07:46:59-07:00weekly0.5https://taurx.com/neuroprotection-of-cholinergic-neurons-with-a-tau-aggregation-inhibitor-and-rivastigmine-in-an-alzheimers-like-tauopathy-mouse-model2026-04-29T07:31:19-07:00weekly0.5https://taurx.com/oral-tau-aggregation-inhibitor-for-alzheimers-disease-design-progress-and-basis-for-selection-of-the-16-mg-day-dose-in-a-phase-3-randomized-placebo-controlled-trial-of-hydromethylthionine-mesylate2024-10-23T02:57:21-07:00weekly0.5https://taurx.com/hydromethylthionine-enhancement-of-central-cholinergic-signalling-is-blocked-by-rivastigmine-and-memantine2024-10-23T03:31:44-07:00weekly0.5https://taurx.com/mechanisms-of-anticholinesterase-interference-with-tau-aggregation-inhibitor-activity-in-a-tau-transgenic-mouse-model2024-10-23T03:39:47-07:00weekly0.5https://taurx.com/concentration-dependent-activity-of-hydromethylthionine-on-cognitive-decline-and-brain-atrophy-in-mild-to-moderate-alzheimers-disease2024-10-23T03:41:06-07:00weekly0.5